

Thomas S Harrison

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8913642/thomas-s-harrison-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

10,877
citations

53
h-index

102
g-index

183
ext. papers

13,233
ext. citations

9.6
avg, IF

5.95
L-index

#	Paper	IF	Citations
169	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease.. <i>Aids</i> , 2022 ,	3.5	1
168	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.. <i>New England Journal of Medicine</i> , 2022 , 386, 1109-1120	59.2	13
167	Tackling the emerging threat of antifungal resistance to human health.. <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	18
166	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022 , 305, 115082	5.1	0
165	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021 , 11, e039191	3	2
164	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009376	4.8	1
163	Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1584-1586	3.8	3
162	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. <i>Journal of Infection</i> , 2021 , 82, 90-97	18.9	5
161	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1268-1278	11.6	14
160	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , 2021 , 21, 16-18	25.5	5
159	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab066	1	3
158	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy-Naïve and -Experienced Patients in Sub-Saharan Africa. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab397	1	1
157	Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment: a case report of coincidental racemose neurocysticercosis. <i>BMC Infectious Diseases</i> , 2021 , 21, 724	4	
156	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021 , 22, 1266	1.4	2
155	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	12
154	Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. <i>International Journal of Infectious Diseases</i> , 2020 , 95, 459-461	10.5	5
153	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa489	1	4

152	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
151	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020 , 99, e22606	1.8	1
150	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020 , 34, 1425-1428	3.5	4
149	Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa. <i>BMC Infectious Diseases</i> , 2020 , 20, 555	4	3
148	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020 , 59,	9.7	5
147	HIV-1C and Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020 , 12,	6.2	1
146	Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1652-1657	11.6	4
145	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. <i>Clinical Infectious Diseases</i> , 2020 , 70, 521-524	11.6	10
144	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 26-29	11.6	8
143	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1683-1690	11.6	22
142	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	6
141	Reply to Rajasingham and Boulware. <i>Clinical Infectious Diseases</i> , 2019 , 69, 732-735	11.6	2
140	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019 , 69, 588-595	11.6	9
139	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019 , 68, 393-401	11.6	47
138	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts. <i>Clinical Infectious Diseases</i> , 2019 , 68, 688-698	11.6	28
137	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 999-1014	15.9	57
136	Recent advances in managing HIV-associated cryptococcal meningitis. <i>F1000Research</i> , 2019 , 8,	3.6	7
135	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. <i>Southern African Journal of HIV Medicine</i> , 2019 , 20, 1030	1.4	17

134	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019 , 9, e026288	3	3
133	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019 , 10,	7.8	22
132	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. <i>Aids</i> , 2019 , 33, 1539-1541	3.5	
131	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , 2019 , 19, e143-e147	25.5	35
130	Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1122-1132	11.6	37
129	Advances in the diagnosis and treatment of fungal infections of the CNS. <i>Lancet Neurology</i> , 2018 , 17, 362-372	24.1	62
128	Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 724-731	5.1	12
127	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018 , 378, 1004-1017	59.2	183
126	Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. <i>HIV Medicine</i> , 2018 , 19, e47-e48	2.7	2
125	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2018 , 66, 686-692	11.6	61
124	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. <i>Frontiers in Microbiology</i> , 2018 , 9, 409	5.7	35
123	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis. <i>PLoS Pathogens</i> , 2018 , 14, e1006978	7.6	69
122	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. <i>Practical Neurology</i> , 2018 , 18, 166-169	2.4	5
121	The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options. <i>Medical Mycology Case Reports</i> , 2018 , 19, 9-12	1.7	3
120	Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. <i>Aids</i> , 2018 , 32, 2259-2261	3.5	2
119	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018 , 19, 649	2.8	26
118	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018 , 9,	7.8	4
117	Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. <i>BMC Infectious Diseases</i> , 2018 , 18, 520	4	6

116	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycological Lateral Flow Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 574-578	3.1	13
115	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017 , 2,	5	185
114	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017 , 7, 1165-1176	2.2	49
113	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
112	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014. <i>Journal of Infection</i> , 2017 , 74, 260-271	18.9	12
111	The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies. <i>PLoS ONE</i> , 2017 , 12, e0171917	3.7	18
110	Fungal infections in HIV/AIDS. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, e334-e343	25.5	201
109	Cryptococcal meningitis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017 , 78, C125-C127	3.8	4
108	Itraconazole and antiretroviral therapy: strategies for empirical dosing - Author's reply. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1123-1124	25.5	1
107	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	28
106	Tracing Genetic Exchange and Biogeography of var. at the Global Population Level. <i>Genetics</i> , 2017 , 207, 327-346	4	57
105	Genomic epidemiology of Cryptococcus yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. <i>Molecular Ecology</i> , 2017 , 26, 1991-2005	5.7	37
104	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017 , 13, 13-24	15	222
103	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005575	4.8	33
102	Immune correlates of HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2017 , 13, e1006207	7.6	15
101	XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing. <i>Journal of Infection</i> , 2016 , 73, 210-8	18.9	17
100	Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 581-587	11.6	74
99	Forgotten but not gone: HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 756-758	25.5	14

98	A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016 , 20, 832-8	2.1	28
97	Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. <i>Journal of Infection</i> , 2015 , 70, 668-75	18.9	28
96	Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2015 , 11, e1004754	7.6	86
95	Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 2173-82	40	151
94	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7224-31	5.9	69
93	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 276	2.8	21
92	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003847	4.8	65
91	Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1473-83	9.7	74
90	High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <i>New England Journal of Medicine</i> , 2014 , 371, 1599-608	59.2	301
89	A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2014 , 9, e110285	3.7	43
88	Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. <i>MBio</i> , 2014 , 5, e00725-13	7.8	19
87	<i>Cryptococcus neoformans</i> ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2014 , 209, 74-82	7	74
86	Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. <i>Clinical Infectious Diseases</i> , 2014 , 58, 736-45	11.6	234
85	Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2014 , 59, 493-500	11.6	9
84	Access to antifungal medicines in resource-poor countries - authorsReply. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 371	25.5	4
83	Systemic fungal infections. <i>Medicine</i> , 2014 , 42, 26-30	0.6	3
82	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2000-8	15.9	88
81	Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2793-800	5.9	46

80	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 629-37	25.5	112
79	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. <i>Journal of Infection</i> , 2013 , 66, 75-9	18.9	27
78	The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1817-28	7	91
77	Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. <i>Journal of Infectious Diseases</i> , 2013 , 208, 351-61	7	38
76	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013 , 26, 26-34	5.4	53
75	Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting. <i>International Journal of STD and AIDS</i> , 2013 , 24, 263-8	1.4	2
74	Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2435-44	5.1	81
73	Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. <i>PLoS ONE</i> , 2013 , 8, e69288	3.7	96
72	A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2013 , 8, e67311	3.7	45
71	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012 , 64, 76-81	18.9	62
70	Immunotherapy for fungal infections. <i>Current Opinion in Microbiology</i> , 2012 , 15, 434-9	7.9	22
69	Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012 , 11, 374-9		48
68	Early clinical and subclinical visual evoked potential and Humphrey® visual field defects in cryptococcal meningitis. <i>PLoS ONE</i> , 2012 , 7, e52895	3.7	16
67	Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2012 , 54, 121-8	11.6	102
66	Reply to Lee and Newton. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1745-1746	11.6	
65	Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4471-3	5.9	25
64	Adjunctive interferon- γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. <i>Aids</i> , 2012 , 26, 1105-13	3.5	192
63	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012 , 26, 1363-70	3.5	60

62	Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1019-23	11.6	229
61	Prevention of AIDS-associated cryptococcosis in resource-poor areas. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 892-4	25.5	3
60	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?. <i>South African Medical Journal</i> , 2011 , 101, 232-4	1.5	19
59	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011 , 63, 484-6	18.9	14
58	Low diversity <i>Cryptococcus neoformans</i> variety <i>grubii</i> multilocus sequence types from Thailand are consistent with an ancestral African origin. <i>PLoS Pathogens</i> , 2011 , 7, e1001343	7.6	62
57	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1815-20	5.1	70
56	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010 , 100, 378-82	1.5	31
55	Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1463-5	11.6	33
54	Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis?. <i>Clinical Infectious Diseases</i> , 2010 , 51, 986-7; author reply 987-9	11.6	7
53	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010 , 24, 405-10	3.5	50
52	Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 668-9	3.1	4
51	<i>Cryptococcus</i> : Spectrum of Disease and Treatment 2010 , 145-165		
50	Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 199-202	1.5	10
49	Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010 , 50, 338-44	11.6	142
48	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010 , 14 Suppl 3, e310-2	10.5	22
47	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , 2010 , 50, 291-322	11.6	1683
46	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010 , 24, 612-4	3.5	18
45	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010 , 24, 1233-5	3.5	22

44	Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010 , 60, 496-8	18.9	38
43	Positive predictive value of the UK clinical case definition for H1N1/09 (Swine) influenza. <i>Journal of Infection</i> , 2010 , 60, 405-7	18.9	4
42	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010 , 10, 67	4	193
41	Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 702-9	11.6	166
40	The burden of HIV-associated cryptococcal disease. <i>Aids</i> , 2009 , 23, 531-2	3.5	26
39	Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 130-4	3.1	146
38	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009 , 49, 812-813	11.6	3
37	Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1486-91	11.6	64
36	Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. <i>Clinical Infectious Diseases</i> , 2009 , 48, 856-62	11.6	244
35	Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1784-6	11.6	5
34	Systemic fungal infections. <i>Medicine</i> , 2009 , 37, 660-664	0.6	1
33	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009 , 23, 1182-3	3.3	69
32	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009 , 23, 701-6	3.5	129
31	High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. <i>Clinical Infectious Diseases</i> , 2008 , 47, 123-30	11.6	209
30	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1110-1111	11.6	2
29	Pulmonary cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008 , 29, 141-50	3.9	71
28	Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1556-61	11.6	151
27	Managing cryptococcosis in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 596-603	5.4	39

26	Immune dysfunction in HIV-seronegative, <i>Cryptococcus gattii</i> meningitis. <i>Journal of Infection</i> , 2007 , 54, e165-8	18.9	32
25	Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1038-42	5.9	51
24	Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naïve or antiretroviral-experienced patients treated with amphotericin B or fluconazole. <i>Clinical Infectious Diseases</i> , 2007 , 45, 76-80	11.6	230
23	Role of capsule and interleukin-6 in long-term immune control of <i>Cryptococcus neoformans</i> infection by specifically activated human peripheral blood mononuclear cells. <i>Infection and Immunity</i> , 2006 , 74, 5302-10	3.7	21
22	Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1069-73	11.6	174
21	Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , 2005 , 5, 530-1	25.5	53
20	Systemic fungal infections. <i>Medicine</i> , 2005 , 33, 116-119	0.6	2
19	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. <i>Journal of Infection</i> , 2005 , 51, e221-4	18.9	45
18	Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2005 , 192, 681-4	7	55
17	Correspondence of in vitro and in vivo fluconazole dose-response curves for <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3297-301	5.9	19
16	IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. <i>Journal of Immunology</i> , 2005 , 174, 1746-50	5.3	129
15	Cryptococcal meningitis. <i>British Medical Bulletin</i> , 2004 , 72, 99-118	5.4	251
14	Intrathecal production and secretion of vascular endothelial growth factor during Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1310-7	7	29
13	Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. <i>Lancet</i> , 2004 , 363, 1764-7	40	368
12	Dengue hemorrhagic fever with fulminant hepatic failure in an immigrant returning to Bangladesh. <i>Clinical Infectious Diseases</i> , 2003 , 37, e1-4	11.6	26
11	<i>Cryptococcus neoformans</i> and cryptococcosis. <i>Journal of Infection</i> , 2000 , 41, 12-7	18.9	25
10	<i>Cryptococcus neoformans</i> resides in an acidic phagolysosome of human macrophages. <i>Infection and Immunity</i> , 1999 , 67, 885-90	3.7	177
9	Chloroquine induces human mononuclear phagocytes to inhibit and kill <i>Cryptococcus neoformans</i> by a mechanism independent of iron deprivation. <i>Journal of Clinical Investigation</i> , 1997 , 100, 1640-6	15.9	93

8	Cryptococcosis in Asia287-297	2
7	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. <i>Wellcome Open Research</i> ,4, 83	4.8
6	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. <i>Wellcome Open Research</i> ,4, 83	4.8
5	Population genomics of <i>Cryptococcus neoformans</i> var. <i>grubii</i> reveals new biogeographic relationships and finely maps hybridization	2
4	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries565-584	
3	A population genomics approach to assessing the genetic basis of within-host microevolution underlying recurrent cryptococcal meningitis infection	4
2	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis	1
1	Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort. <i>Wellcome Open Research</i> ,6, 19	4.8